Related Experiment Video
Updated: Jun 14, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MST1R-targeted therapy in the battle against gallbladder cancer
Wei Wang1, Chao Huang2, Li Zhang3
1Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600 Yishan Road, Shanghai, 200233, China. 7250013144@shsmu.edu.cn.
Background:
Gallbladder cancer (GBC) is characterized by high mortality rate. Our study sought therapeutic candidates for GBC.
Results:
Bioinformatics analysis identified significant upregulation of MST1R in GBC. In vitro experiments demonstrated that the MST1R inhibitor MGCD-265 effectively restrained GBC cell proliferation at lower concentrations. Additionally, it induced cycle arrest and apoptosis in GBC cells in a dose-dependent manner. Mouse models exhibited that MGCD-265 treatment significantly diminished the proliferative capacity of GBC-SD cells. Transcriptomics sequencing revealed significant transcriptome alterations, with 200 transcripts upregulated and 883 downregulated. KEGG and GO analyses highlighted enrichment in processes like cell adhesion and pathways such as protein digestion and absorption. Downstream genes analysis identified JMJD6 upregulation post-MGCD-265 treatment. In vivo experiments confirmed that combining MGCD-265 with the JMJD6 inhibitor SKLB325 enhanced the anticancer effect against GBC.
Conclusion:
Overall, targeting MST1R and its downstream genes, particularly combining MGCD-265 with SKLB325, holds promise as a therapeutic strategy for GBC.
Insights
This study identified MST1R as a therapeutic target for gallbladder cancer (GBC). Inhibiting MST1R with MGCD-265 and combining it with SKLB325 shows promise for GBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gallbladder cancer (GBC) presents a significant clinical challenge due to its high mortality rate.
- Identifying novel therapeutic targets is crucial for improving GBC patient outcomes.
Purpose of the Study:
- To identify potential therapeutic candidates for gallbladder cancer.
- To investigate the role of MST1R and its downstream targets in GBC progression and treatment.
Main Methods:
- Bioinformatics analysis to identify differentially expressed genes in GBC.
- In vitro studies using GBC cell lines to assess the efficacy of MST1R inhibitors.
- In vivo mouse models to evaluate treatment effects on tumor growth.
- Transcriptomics sequencing to analyze global gene expression changes.
- KEGG and GO pathway enrichment analysis.
Main Results:
- MST1R was significantly upregulated in GBC.
- The MST1R inhibitor MGCD-265 demonstrated dose-dependent inhibition of GBC cell proliferation, cell cycle arrest, and apoptosis in vitro and in vivo.
- Transcriptome analysis revealed widespread alterations, with enrichment in cell adhesion and protein digestion pathways.
- JMJD6 was identified as a downstream target upregulated by MGCD-265.
- Combination therapy of MGCD-265 and a JMJD6 inhibitor (SKLB325) enhanced anticancer effects in GBC models.
Conclusions:
- Targeting MST1R represents a promising therapeutic strategy for GBC.
- Combined inhibition of MST1R and its downstream gene JMJD6 may offer enhanced efficacy for GBC treatment.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
